Cargando…
Dysregulation of the Sirt5/IDH2 axis contributes to sunitinib resistance in human renal cancer cells
Sunitinib (Sun), a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, is the standard first‐line treatment against advanced clear cell renal cell carcinoma (RCC), but resistance to therapy is inevitable. Reactive oxygen species production is associated with sensitivity to chem...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7931237/ https://www.ncbi.nlm.nih.gov/pubmed/33455080 http://dx.doi.org/10.1002/2211-5463.13090 |